In final draft guidance, NICE recommended the antibody drug conjugate be used in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) for untreated diffuse large B-cell lymphoma (DLBCL).
Around 5,500 people are diagnosed with DLBCL each year in England. The disease can develop at any age, but most patients are diagnosed at the age of 65 years or older.
Common symptoms include painless swellings at single or multiple sites, excessive night sweating, unexplained fever and weight loss…
